HIV-associated malignancies in sub-Saharan Africa: progress, challenges, and opportunities.
Identifieur interne : 003994 ( Ncbi/Merge ); précédent : 003993; suivant : 003995HIV-associated malignancies in sub-Saharan Africa: progress, challenges, and opportunities.
Auteurs : Lameck Chinula [Malawi] ; Agnes Moses ; Satish GopalSource :
- Current opinion in HIV and AIDS [ 1746-6318 ] ; 2017.
Descripteurs français
- KwdFr :
- MESH :
- diagnostic : Tumeurs.
- traitement médicamenteux : Infections à VIH.
- épidémiologie : Afrique subsaharienne, Tumeurs.
- Humains, Infections à VIH, Résultat thérapeutique, Tumeurs.
English descriptors
- KwdEn :
- MESH :
- complications : HIV Infections.
- diagnosis : Neoplasms.
- drug therapy : HIV Infections.
- epidemiology : Africa South of the Sahara, Neoplasms.
- therapy : Neoplasms.
- Humans, Treatment Outcome.
Abstract
To summarize recent developments for HIV-associated malignancies (HIVAM) in low-income and middle-income countries (LMIC) with particular focus on sub-Saharan Africa (SSA).
DOI: 10.1097/COH.0000000000000329
PubMed: 27607593
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000704
- to stream PubMed, to step Curation: 000704
- to stream PubMed, to step Checkpoint: 000704
Links to Exploration step
pubmed:27607593Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">HIV-associated malignancies in sub-Saharan Africa: progress, challenges, and opportunities.</title><author><name sortKey="Chinula, Lameck" sort="Chinula, Lameck" uniqKey="Chinula L" first="Lameck" last="Chinula">Lameck Chinula</name><affiliation wicri:level="4"><nlm:affiliation>aUNC Project-Malawi, Lilongwe, Malawi bUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA cUniversity of Malawi College of Medicine, Blantyre, Malawi.</nlm:affiliation><country xml:lang="fr">Malawi</country><wicri:regionArea>aUNC Project-Malawi, Lilongwe, Malawi bUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA cUniversity of Malawi College of Medicine, Blantyre</wicri:regionArea><orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName><placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Moses, Agnes" sort="Moses, Agnes" uniqKey="Moses A" first="Agnes" last="Moses">Agnes Moses</name></author><author><name sortKey="Gopal, Satish" sort="Gopal, Satish" uniqKey="Gopal S" first="Satish" last="Gopal">Satish Gopal</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27607593</idno><idno type="pmid">27607593</idno><idno type="doi">10.1097/COH.0000000000000329</idno><idno type="wicri:Area/PubMed/Corpus">000704</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000704</idno><idno type="wicri:Area/PubMed/Curation">000704</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000704</idno><idno type="wicri:Area/PubMed/Checkpoint">000704</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000704</idno><idno type="wicri:Area/Ncbi/Merge">003994</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">HIV-associated malignancies in sub-Saharan Africa: progress, challenges, and opportunities.</title><author><name sortKey="Chinula, Lameck" sort="Chinula, Lameck" uniqKey="Chinula L" first="Lameck" last="Chinula">Lameck Chinula</name><affiliation wicri:level="4"><nlm:affiliation>aUNC Project-Malawi, Lilongwe, Malawi bUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA cUniversity of Malawi College of Medicine, Blantyre, Malawi.</nlm:affiliation><country xml:lang="fr">Malawi</country><wicri:regionArea>aUNC Project-Malawi, Lilongwe, Malawi bUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA cUniversity of Malawi College of Medicine, Blantyre</wicri:regionArea><orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName><placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Moses, Agnes" sort="Moses, Agnes" uniqKey="Moses A" first="Agnes" last="Moses">Agnes Moses</name></author><author><name sortKey="Gopal, Satish" sort="Gopal, Satish" uniqKey="Gopal S" first="Satish" last="Gopal">Satish Gopal</name></author></analytic><series><title level="j">Current opinion in HIV and AIDS</title><idno type="eISSN">1746-6318</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Africa South of the Sahara (epidemiology)</term><term>HIV Infections (complications)</term><term>HIV Infections (drug therapy)</term><term>Humans</term><term>Neoplasms (diagnosis)</term><term>Neoplasms (epidemiology)</term><term>Neoplasms (therapy)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Afrique subsaharienne (épidémiologie)</term><term>Humains</term><term>Infections à VIH ()</term><term>Infections à VIH (traitement médicamenteux)</term><term>Résultat thérapeutique</term><term>Tumeurs ()</term><term>Tumeurs (diagnostic)</term><term>Tumeurs (épidémiologie)</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Africa South of the Sahara</term><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Afrique subsaharienne</term><term>Tumeurs</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Infections à VIH</term><term>Résultat thérapeutique</term><term>Tumeurs</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To summarize recent developments for HIV-associated malignancies (HIVAM) in low-income and middle-income countries (LMIC) with particular focus on sub-Saharan Africa (SSA).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27607593</PMID><DateCreated><Year>2016</Year><Month>09</Month><Day>08</Day></DateCreated><DateCompleted><Year>2017</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2017</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1746-6318</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Current opinion in HIV and AIDS</Title><ISOAbbreviation>Curr Opin HIV AIDS</ISOAbbreviation></Journal><ArticleTitle>HIV-associated malignancies in sub-Saharan Africa: progress, challenges, and opportunities.</ArticleTitle><Pagination><MedlinePgn>89-95</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">To summarize recent developments for HIV-associated malignancies (HIVAM) in low-income and middle-income countries (LMIC) with particular focus on sub-Saharan Africa (SSA).</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Antiretroviral therapy (ART) scale-up is leading to epidemiologic transitions in LMIC similar to high-income countries, with aging and growth of HIV-infected populations, declining infectious deaths, increasing cancer deaths, and transitions from AIDS-defining cancers to non-AIDS defining cancers. Despite ART scale-up, the HIVAM burden remains high including an enormous AIDS-defining cancers burden in SSA. For Kaposi sarcoma, patients treated with ART and chemotherapy can experience good outcomes even in rural SSA, but Kaposi sarcoma heterogeneity remains insufficiently understood including virologic, immunologic, and inflammatory features that may be unique to LMIC. For cervical cancer, scale-up of prevention efforts including vaccination and screening is underway, with benefits already apparent despite continuing high disease burden. For non-Hodgkin lymphoma, curative treatment is possible in the ART era even in SSA, and multifaceted approaches can improve outcomes further. For many other prevalent HIVAM, care and research efforts are being established to guide treatment and prevention specifically in LMIC.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Sustained investment for HIVAM in LMIC can help catalyze a cancer care and research agenda that benefits HIV-positive and HIV-negative patients worldwide.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chinula</LastName><ForeName>Lameck</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>aUNC Project-Malawi, Lilongwe, Malawi bUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA cUniversity of Malawi College of Medicine, Blantyre, Malawi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moses</LastName><ForeName>Agnes</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gopal</LastName><ForeName>Satish</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 TW009488</GrantID><Acronym>TW</Acronym><Agency>FIC NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA190152</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R25 TW009340</GrantID><Acronym>TW</Acronym><Agency>FIC NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 CA210285</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA016086</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U2G PS001965</GrantID><Acronym>PS</Acronym><Agency>NCHHSTP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 CA121947</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 CA121947</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 CA180815</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin HIV AIDS</MedlineTA><NlmUniqueID>101264945</NlmUniqueID><ISSNLinking>1746-630X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>BMC Res Notes. 2012 Mar 16;5:149</RefSource><PMID Version="1">22424105</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Infect Agent Cancer. 2015 Aug 24;10:28</RefSource><PMID Version="1">26306097</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Infect Dis. 2016 Feb 16;16:82</RefSource><PMID Version="1">26883427</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Jul 20;27(21):3480-8</RefSource><PMID Version="1">19470940</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):295-301</RefSource><PMID Version="1">26452066</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):332-339</RefSource><PMID Version="1">27331659</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2009 Apr 2;360(14):1385-94</RefSource><PMID Version="1">19339719</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):66-73</RefSource><PMID Version="1">23797692</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2015 Aug 12;10(8):e0135563</RefSource><PMID Version="1">26266949</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Med. 2016 May;5(5):914-28</RefSource><PMID Version="1">26823008</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2011 Apr;56(4):312-9</RefSource><PMID Version="1">21350364</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2007 Aug 4;370(9585):398-406</RefSource><PMID Version="1">17679017</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncologist. 2016 Jun;21(6):731-8</RefSource><PMID Version="1">27053501</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2015 Apr 17;10(4):e0122169</RefSource><PMID Version="1">25885821</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2014 Sep 20;384(9948):1158</RefSource><PMID Version="1">25241721</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2014 Jul 1;59(1):127-35</RefSource><PMID Version="1">24723284</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2016 Jan 1;138(1):45-54</RefSource><PMID Version="1">26175054</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):150-7</RefSource><PMID Version="1">22395672</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):296-303</RefSource><PMID Version="1">26181812</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2009 Mar 1;48(5):633-9</RefSource><PMID Version="1">19202627</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):481-6</RefSource><PMID Version="1">25844696</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Ophthalmol. 2015 Sep;99(9):1158-61</RefSource><PMID Version="1">25784215</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2016 Jun 30;374(26):2509-11</RefSource><PMID Version="1">27355529</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2006 Feb 15;118(4):985-90</RefSource><PMID Version="1">16106415</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA Ophthalmol. 2015 Nov;133(11):1314-21</RefSource><PMID Version="1">26378623</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Int AIDS Soc. 2015 Aug 03;18:20122</RefSource><PMID Version="1">26242311</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2013 Nov 28;27(18):2933-42</RefSource><PMID Version="1">23921614</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 Apr;14(4):e168-75</RefSource><PMID Version="1">23561748</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2015 Aug 12;10(8):e0135602</RefSource><PMID Version="1">26267867</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):e8-16</RefSource><PMID Version="1">24419071</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Infect Agent Cancer. 2015 Feb 02;10:4</RefSource><PMID Version="1">25685180</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Int AIDS Soc. 2015 May 29;18:19929</RefSource><PMID Version="1">26028156</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2016 Mar 02;11(3):e0150445</RefSource><PMID Version="1">26934054</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2013 Jun 19;27(10 ):1603-13</RefSource><PMID Version="1">23462220</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):547-54</RefSource><PMID Version="1">25393941</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pediatr Blood Cancer. 2013 Aug;60(8):1274-80</RefSource><PMID Version="1">23487320</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Med. 2015 Apr;4(4):588-95</RefSource><PMID Version="1">25641622</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):e20-6</RefSource><PMID Version="1">26322673</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>MBio. 2014 Sep 23;5(5):e01633-14</RefSource><PMID Version="1">25249280</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2006 Aug 31;24 Suppl 3:S3/26-34</RefSource><PMID Version="1">16950015</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA Ophthalmol. 2015 Nov;133(11):1305-13</RefSource><PMID Version="1">26378395</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J R Soc Med. 2015 Feb;108(2):57-67</RefSource><PMID Version="1">25721114</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2014 May;50(8):1472-81</RefSource><PMID Version="1">24636877</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2016 Jun 17;34(29):3420-6</RefSource><PMID Version="1">26704259</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2016 Aug 1;139(3):518-26</RefSource><PMID Version="1">26991686</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2011 May 4;103(9):753-62</RefSource><PMID Version="1">21483021</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 Apr;14(4):e152-7</RefSource><PMID Version="1">23561746</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2016 Sep 15;139(6):1209-16</RefSource><PMID Version="1">27098265</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2016 Apr 15;11(4):e0153335</RefSource><PMID Version="1">27082863</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017954" MajorTopicYN="N">Africa South of the Sahara</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>We have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>01</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27607593</ArticleId><ArticleId IdType="doi">10.1097/COH.0000000000000329</ArticleId><ArticleId IdType="pmc">PMC5241291</ArticleId><ArticleId IdType="mid">NIHMS841622</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Malawi</li></country><region><li>Caroline du Nord</li></region><settlement><li>Chapel Hill (Caroline du Nord)</li></settlement><orgName><li>Université de Caroline du Nord à Chapel Hill</li></orgName></list><tree><noCountry><name sortKey="Gopal, Satish" sort="Gopal, Satish" uniqKey="Gopal S" first="Satish" last="Gopal">Satish Gopal</name><name sortKey="Moses, Agnes" sort="Moses, Agnes" uniqKey="Moses A" first="Agnes" last="Moses">Agnes Moses</name></noCountry><country name="Malawi"><region name="Caroline du Nord"><name sortKey="Chinula, Lameck" sort="Chinula, Lameck" uniqKey="Chinula L" first="Lameck" last="Chinula">Lameck Chinula</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003994 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 003994 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:27607593
|texte= HIV-associated malignancies in sub-Saharan Africa: progress, challenges, and opportunities.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:27607593" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |